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INTRODUCTION
Outcomes for patients with high-risk neuroblastoma remain
poor, with 5-year survival rates of only 30–40% for patients with
stage 4 disease who are >1 year of age [1,2]. Despite multimodal
therapy, complete remission rates remain low, with 15% of patients
progressing and another 33% achieving less than a complete
response during induction [3].
Metaiodobenzylguanidine (MIBG) is an aralkylguanidine
which is structurally similar to the neurotransmitter norepi-
nephrine, and the ganglionic blocking agent guanethidine [4].
Scintigraphic studies in the early 1980s confirmed the effectiveness
of MIBG in localization of both pheochromocytomas [5–8] and
neuroblastomas [9–12]. Until recently, when the Food and Drug
Administration (FDA) approved 123I-MIBG for use in children and
adults, only 131I-MIBG was approved for use in the United States,
although 123I-MIBG has been widely available in Europe [13,14].
Each has the capability to detect neuroblastoma within bone
marrow, cortical bone, or soft tissue [15]. Approximately 90%
of neuroblastomas concentrate MIBG [16–19]. 123I-MIBG scans
have superior image quality, allow single photon emission com-
puted tomography (SPECT) imaging, and deliver a lower radiation
dose to the patient than 131I-MIBG scans. The sensitivity and
specificity of MIBG labeled with either radioiodine isotope has
been high in identifying both primary and metastatic tumors, and
MIBG uptake has been noted in patients with either low or
advanced stage disease, favorable or unfavorable Shimada histo-
logic patterns, amplified or unamplified MYCN gene levels, and
elevated or normal catecholamine levels [16,20].
The role of MIBG uptake as a surrogate marker for overall
response has been examined in many clinical trials [21–27]. Initial
studies made use of the qualitative features of the MIBG scans,
noting whether disease was detectable or not on MIBG scintig-
raphy. Semi-quantitative scoring methods have now been devel-
oped to predict the extent and severity of MIBG avid disease
[21–23]. Using such criteria, the presence of MIBG avid disease
immediately prior to myeloablative therapy has been associated
with later relapse or disease progression [22–24,28].
In the process of attempting to determine an appropriate defi-
nition of an ultra high-risk patient subgroup that may benefit from
alternative therapies in designing a new high-risk trial, it has
proved necessary to compare 123I-MIBG and 131I-MIBG scans
to ensure that survival results are not scan-type dependent.
Since 123I-MIBG did not have FDA approval nor was widely
available at the time Children’s Oncology Group (COG) study
A3973 opened, patients had scans of both types. The goal of this
analysis was not to determine whether 131I-MIBG could replace
123I-MIBG but to evaluate the possibility of combining results in a
single analysis; 123I-MIBG should not be abandoned and remains
the radiolabel of choice because it is the superior scan type for the
many reasons noted above. Rather, instead of excluding the
131I-MIBG scans, or performing separate survival analyses, it
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was necessary to obtain statistical evidence for combining both
types in a single analysis.
A number of studies examining the prognostic impact of MIBG
scintigraphy have combined both 123I-MIBG and 131I-MIBG data
in their analyses [23,24,26,29], whereas others have examined
123I-MIBG scans alone [21,22,30–32]. As most studies have con-
tained significantly greater numbers of 123I-MIBG than 131I-MIBG
scans, limited comparative data can be generated on the efficacy of
one scintigraphic method over the other [23,24,29]. A large com-
parative study of 162 patients undergoing diagnostic imaging with
either 131I-MIBG (99 patients) or 123I-MIBG (63 patients) found no
response advantage with the use of either radioisotope [26]. We
now compare 123I-MIBG and 131I-MIBG scans in predicting sur-
vival for over 300 stage 4 patients treated on COG A3973.
METHODS
Patient Selection and Treatment
Newly diagnosed high-risk patients with International
Neuroblastoma Staging System (INSS) stage 4 neuroblastoma
enrolled on COG protocol A3973 who had completed
123I-MIBG or 131I-MIBG scans at one or more of the following
time points—diagnosis, post-induction, post-transplant, or post-
biotherapy—were included in this analysis. To be eligible for COG
A3973, patients with stage 4 disease had to be aged 30 years or
younger at the time of initial diagnosis. If younger than 12 months,
MYCN amplification (>10 copies) was required; if between 12 and
18 months of age, any unfavorable (MYCN amplification, unfavor-
able histology, and diploid) or unknown biologic feature was
required. Normal renal, cardiac, hepatic, and hematopoietic func-
tion was required, as well as no prior systemic therapy. All patients
had a signed written informed consent approved at the local
Institutional Review Board.
Patients received six cycles of chemotherapy every 21 days,
with Cycles 1, 2, 4, and 6 consisting of cyclophosphamide 4.2 g/
m2, doxorubicin 75 mg/m2, and vincristine 2 mg/m2, and Cycles 3
and 5 including cisplatin 200 mg/m2 and etoposide 600 mg/m2.
Surgical resection of the primary tumor occurred after Cycle 5.
Patients were randomized to either purged or unpurged autologous
stem cell transplant after induction and then received radiation and
13-cis-retinoic acid biologic therapy.
MIBG Scans
Supersaturated potassium iodide was administered, generally
24 hr prior to the diagnostic MIBG dose and subsequently con-
tinued for 3–7 days following the dose, to reduce thyroid accumu-
lation of free radioiodine. Either 123I-MIBG or 131I-MIBG was
administered via intravenous injection over 90 sec (methodology
discussed below). For determination of MIBG scores, 10 different
sites were evaluated, including 9 skeletal sites (head, chest,
T-spine, L-spine, pelvis, upper arms, lower arms, femurs, and
lower legs) and an additional 10th site for soft tissue lesions.
Skeletal sites were individually scored from 0 to 3 as follows:
0 ¼ no MIBG involvement; 1 ¼ one MIBG avid lesion present;
2 ¼ greater than one MIBG avid lesion present; and 3 ¼ MIBG
avidity present in >50% of an individual site. Soft tissue lesions
were scored: 0 ¼ no MIBG involvement; 1 ¼ one MIBG avid soft
tissue lesion present; 2 ¼ greater than one MIBG avid soft tissue
lesion present; and 3 ¼ MIBG avidity in a soft tissue lesion
occupying >50% of the chest or abdomen. A patient’s Curie score
at each time point was calculated as the sum of his/her scores over
all individual sites. The maximum Curie score was 30. All MIBG
scans were centrally reviewed by two nuclear medicine physicians,
without knowledge of the original scan reports or other clinical or
imaging information to validate the data.
123I-MIBG scintigraphy. Planar images with or without
tomographic images were acquired [20]. Typically, for planar
imaging, overlapping anterior and posterior spot views imaging
the entire body are obtained for 10 min each at 24 hr following the
administration of 370 MBq (10 mCi)/1.7 m2 of body surface area
(BSA) of 123I-MIBG. A large field of view dual-head gamma
camera and low-energy collimators were recommended.
Alternately, a low-speed, whole-body scan was acceptable. A
single- or multiheaded camera with a low-energy collimator,
rotated 3608 with 120 projections at 20 sec per stop, was used
for SPECT imaging at 24 hr. Filtered back-projection with a
Butterworth filter and a cut-off frequency of 0.2–0.5 was used
to reconstruct the images.
131I-MIBG scintigraphy. 131I-MIBG scintigraphy is typically
performed 24–48 hr and occasionally 72–96 hr after administering
18.5–37 MBq (0.5–1.0 mCi)/1.7 m2 BSA of 131I-MIBG. Anterior
and posterior views of the head, neck, chest, abdomen, and pelvis
are obtained for 100,000 counts or 20 min [20]. Alternately, a low-
speed, whole-body scan would also be adequate. The use of a dual-
head gamma camera with a large field of view and high-energy
collimators is again preferred. SPECT imaging is not performed
with 131I-MIBG scintigraphy. MIBG loses activity over time due to
radioactive decay; thus anatomic features become less recogniz-
able at later imaging times. However, tumors often become more
evident over time, due to a reduction in surrounding background
levels.
Statistical Analysis
Differences in median Curie scores between the two MIBG
scan types were tested with the two-sided Wilcoxon Rank-Sum test
at each time point. The relationship between 123I-MIBG and 131I-
MIBG scan types and standard prognostic factors age (<18 months
vs. 18 months), MYCN status (not amplified vs. amplified),
ploidy (hyperdiploid vs. diploid), and Shimada histology (favor-
able vs. unfavorable) were examined via Fisher’s exact test.
Time to event for 123I-MIBG versus 131I-MIBG was compared
using log-rank test comparisons of event-free survival (EFS) and
overall survival (OS) at each time point. EFS and OS were calcu-
lated using the method of Kaplan and Meier [33] with standard
errors per Peto et al. [34]. For EFS, time to event was calculated
from diagnosis until the first occurrence of an event (relapse,
progressive disease, secondary malignancy, or death) or until
the time of last contact if no event occurred. For OS, time to
event was calculated from diagnosis until the time of death or last
contact if the patient did not die. At each post-diagnosis time point,
time to event was calculated from the date of the MIBG scan.
Patients who had an event between the diagnosis and post-
diagnosis MIBG scan (post-induction, post-transplant, and post-
biotherapy) went off-study and hence were not included in the
analysis for that particular time point.
Cox proportional hazards (PH) models with the Efron method
of handling tied event times were used to determine the prognostic
strength for survival of the Curie score and scan type in the
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presence of the factors age, MYCN status, and ploidy. Shimada
histology was not included in the models because it is determined
from the mitosis-karyorrhexis index (MKI), grade, diagnosis, and
age and hence confounded with age. However, MKI and grade
were not available as individual variables that could be included in
models in place of histology, and additional models with histology
instead of age were not fit due to only 10 patients having favorable
histology. Any violations of the PH assumption were handled by
treating the covariate as time-dependent and including a covariate
by survival time interaction term in the model [35].
All analyses were performed using SAS1 version 9.2. P-values
<0.05 were considered statistically significant.
RESULTS
Patient Characteristics and MIBG Scans
For the 350 stage 4 patients with at least one MIBG scan,
the median age at diagnosis was 3.1 years (range 6.8 months to
29 years). MYCN amplification was observed in 41% of tumors
analyzed. Diploid tumors were more prevalent (57%) and the
majority of patients had unfavorable histology (97%). No statisti-
cally significant difference in age,MYCN amplification, ploidy, and
histology distribution was found between the 123I-MIBG and
131I-MIBG cohort of patients at any of the time points.
A total of 926 MIBG scans were reviewed, with 683 scans
(74%) utilizing 123I-MIBG and 243 scans (26%) using the
131I-MIBG radiolabel for diagnostic imaging. In 8% (28/350) of
the stage 4 cases, patients switched from one scan modality to the
other during the course of treatment. The remaining 92% of
patients underwent MIBG scintigraphy with the same MIBG
radioisotope throughout their therapy course or only had one scan
performed. Of these, 243/350 (69%) patients had only 123I-MIBG
scans and 79/350 (23%) had only 131I-MIBG scans performed.
There were no differences in median Curie scores between scan
type modalities (123I-MIBG vs. 131I-MIBG) at any of the time
points (Table I).
Survival Analysis
The overall 5-year EFS and OS rates were 33.4  3.6% and
45.6  4.0%, respectively. None of the EFS and OS comparisons
for 123I-MIBG versus 131I-MIBG at any time point were statisti-
cally significant (Table I). The 5-year EFS for the 243 patients with
only 123I-MIBG scans and the 79 patients with only 131I-MIBG
scans were 34.1  4.6% and 39.9  7.1%, respectively (log-rank
P-value ¼ 0.4945), and the 5-year OS rates were 46.5  5.1% and
51.8  7.5%, respectively (log-rank P-value ¼ 0.5409).
At post-induction, 112/302 (37%) patients had a Curie score
above the median value of 0. These 112 patients had a median
Curie score of 3. Patients with Curie score above 0 were found
to have statistically significantly worse EFS (log-rank P-value ¼
0.0009; Fig. 1). A Cox model for EFS indicated that Curie score
and MYCN status were predictive of survival at post-induction,
with Curie scores > 0 corresponding to an increase in the risk of
event of 1.598 and patients with MYCN amplified tumors having
significantly higher risk of event but the effect decreasing over time
(Table II). There was no difference in EFS between 123I-MIBG and
131I-MIBG scan types. The PH assumption was violated forMYCN
status so it was included in the Cox model as a time-varying
covariate with a 1-day difference as the time scale. Curie score
did not maintain independent statistical significance for OS.
DISCUSSION
Historically, the 123I-MIBG scan has been determined to
be more sensitive than the 131I-MIBG scan. In other words,
123I-MIBG shows abnormal areas of uptake more clearly than
131I-MIBG and often shows sites of disease not visualized with
131I-MIBG. This may or may not result in a higher Curie score
in certain patients.
123I-MIBG is clearly the agent of choice for the scintigraphic
depiction of neuroblastoma. The imaging characteristics of the
123I-MIBG label are superior to those of the 131I-MIBG isotope.
123I-MIBG has a lower energy photon more suitable for modern






N Median (range) N Median (range) EFS OS
Diagnosis 218 11 (0–30) 89 8 (0–30) 0.1217 0.9582 0.8283
Post-inductiona 226 0 (0–28) 76 0 (0–20) 0.6024 0.3501 0.5337
Post-transplanta 167 0 (0–24) 62 0 (0–5) 0.1154 0.5333 0.6366
Post-biotherapya 91 0 (0–26) 23 0 (0–5) 0.5353 0.6243 0.2642
MIBG, metaiodobenzylguanidine; N, number of patients; EFS, event-free survival; OS, overall survival. aTime to event for the log-rank test
calculated from the date of the MIBG scan.
Fig. 1. Kaplan–Meier event-free survival curves by post-induction
Curie score with cut-off of 0 and time to event starting from the date of
post-induction metaiodobenzylguanidine (MIBG) scan (log-rank
P-value ¼ 0.0009). N, number of patients.
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gamma cameras and for acquisition of SPECT images. It has a
shorter physical half-life (13.2 hr vs. 8.05 days) and does not have
substantial beta emission, which adds to the radiation burden but
does not contribute to imaging. These characteristics allow about
10-fold higher doses of 123I-MIBG to be administered for the same
radiation burden as 131I-MIBG. Thus, image quality is superior and
normal and abnormal features much more readily identified [20].
In this study, survival analyses did not identify a difference by
scan type at post-induction. For future survival analyses using
MIBG Curie score at post-induction as a possible component in
the definition of an ultra high-risk group, the particular isotope of
the radioiodine label may be ignored since the survival predictive
ability is similar for 123I-MIBG and 131I-MIBG. A multivariate
analysis with other clinical factors including age, MYCN amplifi-
cation, and ploidy showed that Curie score at post-induction is an
independent prognostic marker of EFS. When 123I-MIBG and 131I-
MIBG were compared directly, Curie score was similarly predic-
tive of outcome for the two scan types. In future studies or in meta-
analyses, this statistical analysis will allow us to combine Curie
score data at post-induction from both isotopes in assessing
survival.
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